Smallpox Pipeline | Companies- Chimerix, BioFactura, Tonix Pharmaceuticals Holding Corp, Bavarian Nordic A/S, ViRAZE, HK inno.N, and Others

DelveInsight's, "Smallpox Pipeline Insight 2023" report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Smallpox pipeline landscape. It covers the Smallpox pipeline drug profiles, including Smallpox clinical trials and nonclinical stage products. It also covers the Smallpox therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

To explore more information on the latest breakthroughs in the Smallpox Pipeline treatment landscape of the report, click here @ Smallpox Pipeline Outlook- https://www.delveinsight.com/sample-request/smallpox-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Smallpox Pipeline Report
• DelveInsight's Smallpox Pipeline report depicts a robust space with 04+ active players working to develop 04+ pipeline therapies for Smallpox treatment.
• The leading Smallpox Companies include Chimerix, BioFactura, Tonix Pharmaceuticals Holding Corp, Bavarian Nordic A/S, ViRAZE, HK inno.N, and others.
• The promising Smallpox therapies include FD MVA-BN, Vaccinia virus: ACAM2000 smallpox vaccine, MVA-BN® (IMVAMUNE), TPOXX, and others.
• Food and Drug Administration with a Prescription Drug User Fee Act (PDUFA) date of July 7, 2022. BCV is designed to improve treatment of viral infections by enhancing drug delivery to the intracellular site of viral replication. BCV effectively penetrates cells via its lipid conjugate, releasing the nucleotide analog cidofovir, which then acts to inhibit virus replication.
• TNX-801 is a novel, live virus vaccine grown in cell culture.1 Tonix is developing TNX-801 as a potential smallpox preventing vaccine for widespread immunization and national stockpile. Though it shares structural characteristics with vaccinia-based vaccines, TNX-801 has unique properties that Tonix believes it may lower toxicity and offer potential safety advantages over existing vaccinia-based vaccines, which have been associated with adverse side effects such as myocarditis/pericarditis. *Brincidofovir (BCV) is an oral antiviral being developed for the treatment of smallpox under the U.S.
• Food and Drug Administration's Animal Efficacy Rule, which allows for testing of investigational drugs in animal models to support effectiveness in diseases that are not ethical or feasible to study in humans. BCV is currently under review for approval at the U.S.

For further information, refer to the detailed Smallpox Unmet Needs, Smallpox Market Drivers, and Smallpox Market Barriers, click here for Smallpox Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/smallpox-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Smallpox Overview
Smallpox is an acute contagious disease caused by the variola virus, a member of the orthopoxvirus family. It was one of the most devastating diseases known to humanity and caused millions of deaths before it was eradicated. Smallpox is a category A pathogen which are those organisms/biological agents that pose the highest risk to national security and public health because they can be easily disseminated or transmitted from person to person, result in high mortality rates and have the potential for major public health impact, might cause public panic and social disruption, and require special action for public health preparedness.

Request a sample and discover the recent advances in Smallpox Ongoing Clinical Trial Analysis and Medications, click here @ Smallpox Treatment Landscape- https://www.delveinsight.com/sample-request/smallpox-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Smallpox Emerging Drugs Profile
• Brincidofovir: Chimerix
Brincidofovir (BCV) is an oral antiviral being developed for the treatment of smallpox under the U.S. Food and Drug Administration's Animal Efficacy Rule, which allows for testing of investigational drugs in animal models to support effectiveness in diseases that are not ethical or feasible to study in humans. BCV is currently under review for approval at the U.S.
Food and Drug Administration with a Prescription Drug User Fee Act (PDUFA) date of July 7, 2022. BCV is designed to improve treatment of viral infections by enhancing drug delivery to the intracellular site of viral replication. BCV effectively penetrates cells via its lipid conjugate, releasing the nucleotide analog cidofovir, which then acts to inhibit virus replication.
• TNX-801: Tonix Pharmaceuticals Holding Corp
TNX-801 is a novel, live virus vaccine grown in cell culture.1 Tonix is developing TNX-801 as a potential smallpox preventing vaccine for widespread immunization and national stockpile. Though it shares structural characteristics with vaccinia-based vaccines, TNX-801 has unique properties that Tonix believes it may lower toxicity and offer potential safety advantages over existing vaccinia-based vaccines, which have been associated with adverse side effects such as myocarditis/pericarditis.

Dive deep into rich insights for drugs for Smallpox Market Drivers and Smallpox Market Barriers, click here @ Smallpox Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/smallpox-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Smallpox Pipeline Therapeutics Assessment
There are approx. 4+ key companies which are developing the therapies for Smallpox. The companies which have their Smallpox drug candidates in the most advanced stage, i.e. phase preregistration include, Chimerix.

Scope of the Smallpox Pipeline Report
• Coverage- Global
• Companies- Chimerix, BioFactura, Tonix Pharmaceuticals Holding Corp, Bavarian Nordic A/S, ViRAZE, HK inno.N, and others.
• Smallpox Therapies- FD MVA-BN, Vaccinia virus: ACAM2000 smallpox vaccine, MVA-BN® (IMVAMUNE), TPOXX, and others.
• Smallpox Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on Smallpox Mergers and acquisitions, Smallpox Licensing Activities @ Smallpox Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/smallpox-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Smallpox: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Smallpox - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Smallpox Collaboration Deals
9. Late Stage Products (Prergistration)
10. Brincidofovir: Chimerix
11. Drug profiles in the detailed report…..
12. Preclinical and Discovery Stage Products
13. IN-B002: HK inno.N
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Smallpox Key Companies
17. Smallpox Key Products
18. Smallpox- Unmet Needs
19. Smallpox- Market Drivers and Barriers
20. Smallpox- Future Perspectives and Conclusion
21. Smallpox Analyst Views
22. Smallpox Key Companies
23. Appendix

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

This release was published on openPR.